Hims Super Bowl ad downplays risks of compounded drugs

Hims & Hers to Advertise Weight-Loss Shots at the Super Bowl
Telehealth provider will make its big game debut as the semaglutide shortage continues to sustain the firm’s lower-priced injectables.
Hims & Hers Hopes Super Bowl Commercial About Obesity Stands Apart From Pack of Snacks
Hims & Hers, a tele-health start-up, aims to stand apart from dozens of Super Bowl commercials hawking snacks with a spot that discusses obesity
‘Incredibly irresponsible’: Hims Super Bowl ad downplays risks of compounded drugs
A multi-million dollar Super Bowl ad from telehealth company Hims and Hers downplays risks and side effects of compounded weight loss drugs.
Hims & Hers is making a big bet on a Super Bowl ad
The millennial-targeted telehealth company Hims & Hers (HIMS) is spending big bucks on its first ever Super Bowl commercial to hawk its affordable weight-loss treatments.
Hims & Hers to air its first Super Bowl spot, promoting weight loss drugs
The Super Bowl spot is part of a larger campaign as Hims & Hers continues to highlight its weight loss treatments. The ad will air after Feb. 9 in 30-, 15- and 6-second versions on both broadcast and digital channels. The brand worked with Tinuiti on media duties.
Hims & Hers set for Super Bowl ad debut highlighting GLP-1 weight loss drugs
Hims & Hers’ decision to advertise at the Super Bowl represents an ambitious play for the brand as it positions itself in the heart of the ongoing GLP-1 phenomenon.
Thinner Amid Gluttony? Hims & Hers Debut First SB Ads For Weight-Loss Drugs
Telehealth company's spot decries medications from others as "priced for profits, not patients," while its own weight-loss drugs are "affordable."
Hosted on MSN10h
Hims & Hers Health, Inc. (HIMS) Increases Despite Market Slip: Here's What You Need to Know
Hims & Hers Health, Inc. (HIMS) closed the latest trading day at $31.86, indicating a +1.01% change from the previous session's end. The stock exceeded the S&P 500, which registered a loss of 0.47% ...
Hims & Hers: Potential Risks Ahead, But Shorting May Be Premature
Hims & Hers may leverage FDA compounding exemptions to further extend its compounded GLP-1 offerings. Learn why HIMS stock is ...
FiercePharma1d
Hims & Hers tackles pharma industry drug pricing in Super Bowl ad for compounded GLP-1s
Telehealth company Hims & Hers is playing offense in a new commercial slated to air during the Super Bowl next month. | Telehealth company Hims & Hers is playing offense in a new commercial slated to ...
KVIA1h
New study reveals what Americans perceive as ideal weight
Hers shares information about the average weight for women in the U.S., what women believe the ideal weight is, and the ...
Is Hims & Hers Stock in Trouble?
Hims & Hers Health ( HIMS 6.30%) is coming off a fantastic year in 2024 when its share price skyrocketed 172%. The telehealth ...
Hims & Hers: Ready To Outperform Further
Discover why Hims & Hers Health is a top telehealth leader with impressive growth potential and a promising future for ...
Campaign US1d
Hims & Hers has a new definition for ‘This is America’
Hims & Hers and similar companies allow consumers to make virtual appointments with healthcare providers and obtain ...
bovnews1d
Hims & Hers Health Inc (HIMS) Stock Dilemma: A Drop That Has Everyone Talking—What’s the Real Story?
Hims & Hers Health Inc (HIMS) stock saw a decline, ending the day at $30.51 which represents a decrease of $-0.36 or -1.17% from the prior close of $30.87. The stock opened at $29.28 and touched a low ...